Literature DB >> 26407827

KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study.

Silvia Park1, Kihyun Kim1, Jun Ho Jang1, Seok Jin Kim1, Won Seog Kim1, Eun-Suk Kang2, Chul Won Jung3.   

Abstract

Receptors on natural killer (NK) cells, named killer immunoglobulin-like receptors (KIRs), recognize HLA class I alleles. Patients (n=59) who received allogeneic hematopoietic stem cell transplantation (HSCT) from either a related (n=17) or unrelated donor (n=42) in Samsung Medical Center (Seoul, South Korea) were included. KIR mismatch was defined as incompatibility between the donor KIR and recipient KIR ligand (receptor-ligand model), and all cases were classified into the two broad haplotypes of KIR A and B. Patients with acute leukemia (n=51, 86.4%) or myelodysplastic syndrome (n=8, 13.6%) were included. Peripheral blood was used as the source of stem cells in all patients. Kaplan-Meier survival curves for overall survival (OS), disease-free survival (DFS), and cumulative incidence of relapse (CIR) favored recipients with a KIR-mismatched donor, although the differences were not statistically significant. In multivariate analysis, KIR mismatch was an independent prognostic indicator of a better OS (P=0.010, HR=0.148, 95% CI 0.034-0.639), DFS (P=0.022, HR=0.237, 95% CI 0.069-0.815), and CIR (P=0.031, HR=0.117, 95% CI 0.017-0.823). OS, DFS, and CIR did not differ significantly between the KIR A and B haplotypes.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; Alloreactivity; KIR; NK cell

Mesh:

Substances:

Year:  2015        PMID: 26407827     DOI: 10.1016/j.humimm.2015.09.009

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  7 in total

1.  Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation.

Authors:  Yanmin Zhao; Fei Gao; Yibo Wu; Jimin Shi; Yi Luo; Yamin Tan; Jian Yu; Xiaoyu Lai; Mingming Zhang; Wei Zhang; He Huang
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

2.  Changes of immune cells in patients with hepatocellular carcinoma treated by radiofrequency ablation and hepatectomy, a pilot study.

Authors:  Zusheng Yu; Guowei Li; Hang Yu; Tetsuya Asakawa
Journal:  Open Life Sci       Date:  2021-09-18       Impact factor: 0.938

Review 3.  KIR in Allogeneic Hematopoietic Stem Cell Transplantation: Need for a Unified Paradigm for Donor Selection.

Authors:  Adèle Dhuyser; Alice Aarnink; Michaël Pérès; Jyothi Jayaraman; Neda Nemat-Gorgani; Marie Thérèse Rubio; John Trowsdale; James Traherne
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

Review 4.  Selection and expansion of natural killer cells for NK cell-based immunotherapy.

Authors:  Petra S A Becker; Garnet Suck; Paulina Nowakowska; Evelyn Ullrich; Erhard Seifried; Peter Bader; Torsten Tonn; Christian Seidl
Journal:  Cancer Immunol Immunother       Date:  2016-01-25       Impact factor: 6.968

5.  Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma.

Authors:  Young Bae Choi; Meong Hi Son; Hee Won Cho; Youngeun Ma; Ji Won Lee; Eun-Suk Kang; Keon Hee Yoo; Jung Hyun Her; Okjae Lim; Miyoung Jung; Yu Kyeong Hwang; Ki Woong Sung; Hong Hoe Koo
Journal:  PLoS One       Date:  2019-12-13       Impact factor: 3.240

Review 6.  Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation.

Authors:  Fei Gao; Yishan Ye; Yang Gao; He Huang; Yanmin Zhao
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

7.  Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML.

Authors:  Will P Bultitude; Jennifer Schellekens; Richard M Szydlo; Chloe Anthias; Sarah A Cooley; Jeffrey S Miller; Daniel J Weisdorf; Bronwen E Shaw; Chrissy H Roberts; Christian A Garcia-Sepulveda; Julia Lee; Rachel M Pearce; Marie C Wilson; Michael N Potter; Jenny L Byrne; Nigel H Russell; Stephen MacKinnon; Adrian J Bloor; Amit Patel; I Grant McQuaker; Ram Malladi; Eleni Tholouli; Kim Orchard; Victoria T Potter; J Alejandro Madrigal; Neema P Mayor; Steven G E Marsh
Journal:  Bone Marrow Transplant       Date:  2020-03-13       Impact factor: 5.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.